Table of Contents
[Management of cannabinoid hyperemesis syndrome].
Clinical review outlines management approaches for cannabinoid hyperemesis syndrome affecting one-third of regular cannabis users.
This clinical review consolidates current understanding of CHS presentation and management strategies. The pathognomonic hot water relief behavior remains a key diagnostic feature, though the underlying mechanisms remain incompletely understood.
CHS is increasingly recognized in clinical practice as cannabis use becomes more prevalent and potent. Clinicians need systematic approaches to diagnosis and management of this paradoxical cannabis toxicity syndrome.
| Study Type | Clinical Review |
| Population | Cannabis users experiencing cannabinoid hyperemesis syndrome |
| Intervention | Clinical management strategies including hot water therapy |
| Comparator | Not applicable |
| Primary Outcome | Clinical manifestations and treatment approaches |
| Key Finding | CHS affects approximately one-third of regular cannabis users with characteristic hot water relief pattern |
| Journal | Revue Medicale Suisse |
| Year | 2024 |
CHS should be considered in any regular cannabis user presenting with cyclic vomiting and compulsive hot water bathing behavior. Cannabis cessation remains the definitive treatment, though supportive care can help manage acute episodes.
This review does not provide new mechanistic insights or novel treatment data. The one-third prevalence figure lacks methodological detail, and optimal management protocols remain empirically derived rather than evidence-based.
The prevalence estimate may be imprecise given diagnostic challenges and selection bias in reported cases. Treatment recommendations appear largely based on case series rather than controlled studies.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →CHS is a real clinical entity with characteristic features that clinicians should recognize. Management remains supportive with cannabis cessation as the only definitive intervention, highlighting the need for better treatment research.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is cannabinoid hyperemesis syndrome (CHS)?
CHS is a condition characterized by recurrent episodes of vomiting, nausea, and abdominal pain that affects approximately one-third of regular cannabis users. The syndrome is directly related to chronic cannabis use and can significantly impact quality of life.
What is the most characteristic symptom that helps identify CHS?
The hallmark sign of CHS is that patients find temporary relief from symptoms by taking hot baths or showers. This unique behavior pattern helps distinguish CHS from other causes of cyclic vomiting and is an important diagnostic clue.
How common is CHS among cannabis users?
According to this research, CHS affects approximately one-third of regular cannabis users. This represents a significant prevalence that clinicians should be aware of when evaluating patients with unexplained vomiting who use cannabis.
What is the primary treatment approach for CHS?
The most effective treatment for CHS is complete cessation of cannabis use. While supportive care can help manage acute symptoms, discontinuing cannabis is essential for long-term resolution of the syndrome.
Should I suspect CHS in patients with unexplained vomiting?
Yes, CHS should be considered in any patient presenting with recurrent vomiting, especially if they report cannabis use and find relief with hot showers or baths. A thorough cannabis use history is essential, as patients may not voluntarily disclose their usage patterns.
![[Management of cannabinoid hyperemesis syndrome]. 2 CED Clinic logo](https://cedclinic.com/wp-content/uploads/2026/04/IMG_2201-copy.jpeg)
![[Management of cannabinoid hyperemesis syndrome]. 3 Dr. Benjamin Caplan](https://cedclinic.com/wp-content/uploads/2026/04/Caplan-Headshot-4-1.png)